Skip to main content

Advertisement

SpringerLink
Log in

Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Parkin DM, Bray F, Ferlay J, Pisiani P. Global cancer statistics. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol/Hematol. 2006;58:231–41.

    Article  Google Scholar 

  3. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 1996;171:118–24.

    Article  PubMed  CAS  Google Scholar 

  4. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118–23.

    Article  PubMed  CAS  Google Scholar 

  5. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    PubMed  CAS  Google Scholar 

  6. Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35:335–9.

    Article  PubMed  CAS  Google Scholar 

  7. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a CERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.

    Article  PubMed  CAS  Google Scholar 

  8. Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German multicenter study. Ann Oncol. 2007;18:1652–9.

    Article  PubMed  CAS  Google Scholar 

  9. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost effectiveness. Ann Surg. 2005;242:235–43.

    Article  PubMed  Google Scholar 

  10. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell’Italia Meridionale. Cancer. 2002;94:902–10.

    Article  PubMed  CAS  Google Scholar 

  11. Heinemann V, Quietsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–52.

    Article  PubMed  CAS  Google Scholar 

  12. Sultana A, Ghaneh P, Cunningham D, et al. Gemcitabine based combination chemotherapy in advanced pancreatic cancer – indirect comparison. BMC Cancer. 2008;8:192–7.

    Google Scholar 

  13. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (fixed-dose rate-infusion versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol. 2006;24:933.

    Google Scholar 

  14. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, et al. Cisplatin–gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997;15:297–303.

    PubMed  CAS  Google Scholar 

  15. Hitt R, Castellano D, Hidalgo M, Garcia-Carbonero R, Pena M, Brandariz A, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol. 1998;9:1347–9.

    Article  PubMed  CAS  Google Scholar 

  16. Byrne MJ, Davidson JA, Musk AW, Dewa J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30.

    PubMed  CAS  Google Scholar 

  17. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876–81.

    PubMed  CAS  Google Scholar 

  18. Peters GJ, Bergmann AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22:72–9.

    PubMed  CAS  Google Scholar 

  19. Van Moorsel CJA, Veerman G, Bergman AM, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol. 1997;24:S7–S23.

    PubMed  Google Scholar 

  20. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol. 1996;23:72–6.

    PubMed  CAS  Google Scholar 

  21. Waud WR, Gilbert KS, Grindey GB, Worzalla JF. Lack of in vivo cross-resistance with gemcitabine against drug-resistant murine P388 leukemias. Cancer Chemother Pharmacol. 1996;38:178–80.

    Article  PubMed  CAS  Google Scholar 

  22. Philip PA, Zalupski M, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569–77.

    Article  PubMed  CAS  Google Scholar 

  23. Nguyen B, Sandler A, Denham C. The safety and efficacy of gemcitabine plus cisplatin in the elderly chemonaive NSCLC patients. Proc Am Soc Clin Oncol. 1999;18:1818.

    Google Scholar 

  24. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006;26:9377–86.

    Article  PubMed  CAS  Google Scholar 

  25. Stoecklein NH, Luebke AM, Erbersdobler A, Knoefel WT, Schraut W, Verde PE, et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004;22:4737–45. Erratum in: J Clin Oncol. 2005;23:248.

    Article  PubMed  CAS  Google Scholar 

  26. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer. 2007;120:906–17.

    Article  PubMed  CAS  Google Scholar 

  27. Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29–37.

    Article  PubMed  Google Scholar 

  28. Heinrich S, Schaefer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014–22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Germany

    A. Alexander, A. Rehders, R. Riediger & W. T. Knoefel

  2. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Germany

    M. Schmitt

  3. Institut für Pathologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Germany

    M. Anlauf

Authors
  1. A. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Rehders
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Riediger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. T. Knoefel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Rehders.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alexander, A., Rehders, A., Riediger, R. et al. Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin. J Gastrointest Canc 43 (Suppl 1), 42–45 (2012). https://doi.org/10.1007/s12029-012-9380-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-012-9380-7

Keywords

Search

Navigation